Wafik El-Deiry: Toward a Biomedical Research Enterprise That Better Serves the United States

Wafik El-Deiry shared a post on LinkedIn about a recent paper by Albert Reece et al. published in The New England Journal of Medicine homepage.

“Toward a Biomedical Research Enterprise That Better Serves the United States”

Authors: Albert Reece and Victor Dzau.

“Toward a Biomedical Research Enterprise That Better Serves the United States.

‘The decline of the U.S. biomedical research enterprise would have grave implications not only for scientific progress but also for the national health, economy, and overall prosperity.

‘We can easily imagine a future in which the United States no longer leads the pack in biomedical innovations and medical breakthroughs’.

‘We need a strategic vision and oversight body, as well as enhanced coordination at the national level’.

‘Because of silos and lack of coordination, redundant investigations occur in parallel, and important research questions are left unexplored’.

‘We need a workforce that is adequately compensated and able to focus on the issues that matter most’.

‘It is essential to act now, and act with purpose, to strengthen and reinvigorate the U.S. biomedical research enterprise.’ ”

Source: Wafik El-Deiry/LinkedIn

Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals.

He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.